Alembic Pharmaceuticals secured USFDA approval to market generic Ticagrelor tablets, 90 mg, aimed at preventing heart attack ...

Alembic Pharmaceuticals (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ticagrelor Tablets, ...

Doug Long, VP, industry relations, IQVIA, examines shifting pharmaceutical trends, including specialty growth, biosimilar ...

Vadodara: Alembic Pharmaceuticals Limited has announced that the US Food & Drug Administration (USFDA) has given final ...

Alembic Pharmaceuticals has received USFDA approval to market generic Ticagrelor Tablets, a medication for preventing heart ...

Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche ...

Alembic Pharmaceuticals announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ticagrelor Tablets, 90 mg, and ...

IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market.

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Drug distributor Cardinal Health on Thursday raised its fiscal 2025 adjusted profit forecast for the fourth time, betting on strong demand for costly specialty medicines and branded drugs.

Lilly's weekly prescription data for Zepbound is up 354% year-over-year, while Novo's Wegovy is up just 61%. That's based on ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $227.67, ...